Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review by Chouaïd C, Crequit P, Borget I, Vergnenegre A

Get full text

Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France by Pignata M, Chouaid C, Le Lay K, Luciani L, McConnachie C, Gordon J, Roze S

Get full text

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France by Taipale K, Winfree KB, Boye M, Basson M, Sleilaty G, Eaton J, Evans R, Chouaid C

Get full text

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer by Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG, Heigener DF, Walzer S

Get full text

Cost analysis of adverse events associated with non-small cell lung cancer management in France by Chouaid C, Loirat D, Clay E, Millier A, Godard C, Fannan A, Lévy-Bachelot L, Angevin E

Get full text

Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy by Dalon F, Devouassoux G, Belhassen M, Nachbaur G, Correia Da Silva C, Sail L, Jacoud F, Chouaid C, Van Ganse E

Get full text

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe by Walleser S, Ray J, Bischoff H, Vergnenègre A, Rosery H, Chouaid C, Heigener D, de Castro Carpeño J, Tiseo M, Walzer S

Get full text